Amgen Inc. (AMGN)

Biotechnology medicines maker, 59% in the U.S.. Read October 3, 2026 from the annual report for the period ending December 31, 2025, filed February 13, 2026. Ranked 30 of the 41 Healthcare companies read so far, by the share within reach now.

The filing states approximately 31,500 staff members, 13,000 outside the United States, in one medicines business, so one pattern carries the whole workforce (c).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 18% now, 33% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 56% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

31,500 employees as of December 31, 2025 (stated). Approximately 13,000 of 31,500 staff members are outside the United States.

The filing: “As of December 31, 2025, Amgen had approximately 31,500 staff members in over 50 countries, including approximately 13,000 staff members outside the United States, and we continue to experience overall low turnover rates.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 31,500 staff members in over 50 countries, 13,000 outside the United States; independent contractors, contingent and temporary workers supplement the workforce and are not counted; some employees outside the United States are represented by unions or works councils.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)18% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)19% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)18% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)18% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)18% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)18% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)18% now, 41% by 2028
• Viatris Inc. (VTRS, 30,000 employees)18% now, 41% by 2028

What the filing says about AI

21 sentences in the filing name AI. The filing names AI in its glossary and among the subjects of staff upskilling in 2025, and describes the EU Artificial Intelligence Act among the regulations it faces.

• “Term Description 2017 Tax Act Tax Cuts and Jobs Act of 2017 340B Program Federal 340B Drug Pricing Program AI artificial intelligence Amended 2009 Plan Amended and Restated 2009 Equity Incentive Plan AOCI accumulated other comprehensive income (loss) AstraZeneca AstraZeneca plc ASU Accounting Standards Update ATMOS Amgen Technology and Medical Organizations B-ALL B-cell acute lymphoblastic leuk...”
• “Further, in 2024, the EU Artificial Intelligence (AI) Act, formally known as Regulation (EU) 2024/1689, was passed into law.”
• “The regulation establishes a risk-based framework governing the development, deployment and use of AI systems across the EU.”
• “High-risk AI systems are subject to stringent requirements such as mandatory risk assessments, technical documentation, bias mitigation and explainability standards.”
• “In 2025, we invested in general upskilling of our staff on skills for the future, including topics such as AI.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20234median 1
• Fiscal 202416median 4
• Fiscal 202521median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• One pattern by description (c): the filing counts no staff by function.

Source: the company's annual report on EDGAR, accession 0000318154-26-000010, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.